Auxilium Pharmaceuticals, Inc.  

(Public, NASDAQ:AUXL)   Watch this stock  
+0.67 (1.98%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.85 - 35.03
52 week 17.10 - 35.03
Open 33.85
Vol / Avg. 3.53M/1.11M
Mkt cap 1.77B
P/E     -
Div/yield     -
EPS -3.27
Shares 51.02M
Beta 0.65
Inst. own 131%
Feb 26, 2015
Q4 2014 Auxilium Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 27, 2015
Auxilium Pharmaceuticals Inc Extraordinary Shareholders Meeting - 7:48AM EST - Add to calendar
Oct 30, 2014
Q3 2014 Auxilium Pharmaceuticals Inc Earnings Release
Oct 9, 2014
Endo International Plc Conference Call to Discuss Acquisition of Auxilium Pharmaceuticals Inc - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -29.78% -4.51%
Operating margin -21.16% -16.99%
EBITD margin - -3.47%
Return on average assets -11.59% -2.36%
Return on average equity -76.75% -8.00%
Employees 639 -
CDP Score - -


United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. It market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). XIAFLEX is an injectable clostridial collagenase enzyme approved by the United States Food and Drug Administration (FDA) for the treatment of Dupuytren's contracture (Dupuytren's) in adult patients with a palpable cord. Its Testim is a topical 1% testosterone once-a-day gel that treats hypogonadism by restoring normal testosterone blood levels for a 24-hour period following application and sustaining them in that range when used daily. Testim has been approved for marketing for the indication of male hypogonadism in the United States, Canada, Belgium, Denmark, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In April 2013, it acquired Actient Holdings LLC.

Officers and directors

Rolf A. Classon Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Adrian Adams President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Andrew Saik Chief Financial Officer
Bio & Compensation  - Reuters
Mark A. Glickman Executive Vice President - Marketing & Sales
Age: 48
Bio & Compensation  - Reuters
Benjamin J. Del Tito Jr., Ph.D. Executive Vice President - Regulatory Affairs and Project Management
Age: 58
Bio & Compensation  - Reuters
Alan J. Wills Executive Vice President - Corporate Development
Age: 50
Bio & Compensation  - Reuters
Jennifer L. Armstrong Senior Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters
Andrew I. Koven Chief Administrative Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Elizabeth Varki Jobes Chief Compliance Officer
Age: 47
Bio & Compensation  - Reuters
James P. Tursi M.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters